CoChat

The Fight against Poliovirus Is Not Over

Open access

The DOI matches its Crossref record; 132 of the 137 references it cites were found in a registry or an index; 60 of the 102 sources its claims cite were checked for support.

Abstract

species, and there are three wild PV serotypes: WPV1, WPV2 and WPV3. The launch of the Global Polio Eradication Initiative (GPEI) in 1988 eradicated two of the three serotypes of WPV (WPV2 and WPV3). However, the endemic transmission of WPV1 persists in Afghanistan and Pakistan in 2022. There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV). Between January 2021 and May 2023, a total of 2141 circulating VDPV (cVDPV) cases were reported in 36 countries worldwide. Because of this risk, inactivated poliovirus (IPV) is being used more widely, and attenuated PV2 has been removed from OPV formulations to obtain bivalent OPV (containing only types 1 and 3). In order to avoid the reversion of attenuated OPV strains, the new OPV, which is more stable due to genome-wide modifications, as well as sabin IPV and virus-like particle (VLP) vaccines, is being developed and offers promising solutions for eradicating WP1 and VDPV.

Overview

CoChat Summary

TL;DR

This narrative review summarizes the current epidemiology of wild poliovirus (WPV) and vaccine-derived poliovirus (VDPV) and the vaccine strategies being developed to finish polio eradication. It argues that although WPV2 and WPV3 have been eradicated, WPV1 transmission and cVDPV outbreaks mean the fight against poliovirus is not over.

Key findings

  • Two of three WPV serotypes have been eradicated: WPV2 in 2015 and WPV3 in 2019, but endemic WPV1 transmission persisted in Afghanistan and Pakistan in 2022.
  • Between January 2021 and May 2023, 2141 cVDPV cases were reported in 36 countries: 269 cVDPV1 cases in 6 countries, 1868 cVDPV2 cases in 35 countries, and 4 cVDPV3 cases in Israel; 1629 were AFP cases and 512 were non-AFP cases, with 1055 environmental samples also positive.
  • Reported WPV1 cases included 5 in Afghanistan and Pakistan in 2021 plus 1 in Namibia; in 2022, 2 in Afghanistan, 20 in Pakistan, and 8 in Mozambique; and 1 in Pakistan between January and May 2023.
  • New vaccine approaches include nOPV2, with nearly 600 million doses administered in 28 countries, and sIPV mass vaccination in Sichuan, China, which rapidly suppressed cVDPV2 circulation; remdesivir was reported to clear iVDPV from the stool of a 50-year-old patient.

Methods

  • Narrative review of poliovirus biology, pathogenesis, diagnosis, vaccines, VDPV emergence, and new eradication strategies.
  • Synthesizes published epidemiological reports, WHO/MMWR surveillance data, and clinical trial results; no primary data collection or systematic review methodology is described.
  • Main analysis is descriptive and thematic, covering WPV and VDPV epidemiology and candidate vaccines including nOPV2, sIPV, fractional IPV, and virus-like particles.

Limitations

  • No explicit limitations section is included; the text notes that eradication remains difficult because of persistent transmission foci and challenges in implementing mass immunization programmes.
  • Evident from the text: as a narrative review, it lacks a stated systematic search strategy, inclusion criteria, or quality appraisal, and it relies on cited surveillance reports and trials rather than primary data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/microorganisms11051323

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Pathogenesis of poliomyelitis. The poliovirus is transmitted via the fecal–oral route and reaches the intestinal tract after infecting the oropharynx and surviving the acidity of the stomach. It replicates in lymphoid tissues, such as the tonsils and Peyer’s patches, and is shed in stool for several weeks. From the primary replication sites, the virus spreads to regional lymph nodes (cervical and mesenteric) and the bloodstream, potentially infecting extraneural tissues and amplifying viremia. The poliovirus can breach the intestinal epithelium barrier and cross the blood–brain barrier to reach the central nervous system, where it targets motor neurons located in the ventral horns of the cervical and lumbar regions of the spinal cord.
Figure 1 Pathogenesis of poliomyelitis. The poliovirus is transmitted via the fecal–oral route and reaches the intestinal tract after infecting the oropharynx and surviving the acidity of the stomach. It replicates in lymphoid tissues, such as the tonsils and Peyer’s patches, and is shed in stool for several weeks. From the primary replication sites, the virus spreads to regional lymph nodes (cervical and mesenteric) and the bloodstream, potentially infecting extraneural tissues and amplifying viremia. The poliovirus can breach the intestinal epithelium barrier and cross the blood–brain barrier to reach the central nervous system, where it targets motor neurons located in the ventral horns of the cervical and lumbar regions of the spinal cord.CC BY · PubMed Central
Figure 2 Wild poliovirus circulation in the world in 1988 and between January 2021 and May 2023. (a) In 1988, when the Global Polio Eradication Initiative (GPEI) was launched, polio paralyzed more than 350,000 children in 125 countries. (b) Between January 2021 and May 2023, only one of the three wild poliovirus serotypes, type 1 (WPV1), was circulating in only four countries: Afghanistan, Pakistan, Namibia and Mozambique.
Figure 2 Wild poliovirus circulation in the world in 1988 and between January 2021 and May 2023. (a) In 1988, when the Global Polio Eradication Initiative (GPEI) was launched, polio paralyzed more than 350,000 children in 125 countries. (b) Between January 2021 and May 2023, only one of the three wild poliovirus serotypes, type 1 (WPV1), was circulating in only four countries: Afghanistan, Pakistan, Namibia and Mozambique.CC BY · PubMed Central

Verification

Claims the paper makes

42 Valid · 1 Not valid · 19 Not checked · 6 Own results and interpretations

31 more claims · 17 with their cited sources checked

Create a free account to see all 68 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Research works printed but not linked: 1

  1. Knipe, D.M., and Howley, P.M. (2007). Fields Virology, Lippincott Williams and Wilkins.

Cited by

See all 34

Metadata

Authors
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D.
Affiliations
  • Université de Lille (FR)
  • Marien Ngouabi University (CG)
Corresponding author
Hober, Didier
Venue
Microorganisms
Publisher
MDPI AG
Published
2023-05-17
Volume
11
Issue
5
Pages
1323
ISSN
2076-2607 (ISSN-L)
OpenAlex
W4377103213
Cited by
34
References
137
Citations by year
2026: 7 · 2025: 11 · 2024: 15 · 2023: 1
FWCI
1.31
Type
journal article
Language
en
Open access
Locations
  • Microorganisms (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion, cc-by)
Funders
  • Ministère de l’Education Nationale de la Recherche et de la Technologie (ULR3610, 130771P)
  • “SSHN JEUNE CHERCHEUR” scholarship of Ministère de l’Europe et des Affaires Etrangères and by Campus France (ULR3610, 130771P)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords
poliovirus, wild poliovirus type 1, vaccine-derived poliovirus, oral polio vaccine, inactivated poliovirus vaccine, bivalent oral poliovirus vaccine, virus-like particle vaccine, polio eradication, paralytic poliomyelitis, Global Polio Eradication Initiative

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.